Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Medtronic/Regeneron

This article was originally published in The Gray Sheet

Executive Summary

Medtronic/Regeneron: Firms enter agreement to co-develop "a family of therapeutics for central nervous system diseases and disorders" using experimental Regeneron compounds and Medtronic delivery systems. The initial project under the agreement will be development of Regeneron's Axokine, delivered using a Medtronic implantable pump, for treatment of Huntington's disease. Under terms of the deal, Medtronic has purchased 460,500 shares of Regeneron common stock for $10 mil. and has acquired five-year warrants to buy another 107,400 shares for $21.72 per share. Regeneron will conduct preclinical development of Axokine and "retains all rights to manufacture and commercialize" the drug. Medtronic, which will make milestone payments to Regeneron during the drug's development, retains rights to manufacture and sell the delivery devices, and will receive royalties on sales of drugs developed under the pact...

You may also be interested in...

Medtech Industry Favorite Wins Seat On Powerful House E&C Committee

As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.

Source: 3 Former Obama US CMS Officials Being Considered To Lead Biden’s Medicare Agency

The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.

Hikma Opens Discussions To Acquire GSK OTC, Rx Businesses In Egypt, Tunisia

With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts